Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB805-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human Osteoprotegerin/TNFRSF11B Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from ascites. Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse Osteoprotegerin is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
AAB53709
- Isotype
- IgG
- Antibody clone number
- 69146
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
Molecular cancer therapeutics 2007 Dec;6(12 Pt 1):3219-28
Molecular cancer therapeutics 2007 Dec;6(12 Pt 1):3219-28
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI
Arthritis and rheumatism 2006 May;54(5):1463-72
Arthritis and rheumatism 2006 May;54(5):1463-72
Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.
Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhão H, Resende C, Castelão W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M
Clinical and experimental rheumatology 2005 Mar-Apr;23(2):185-92
Clinical and experimental rheumatology 2005 Mar-Apr;23(2):185-92
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT
The Journal of rheumatology 2005 Apr;32(4):713-20
The Journal of rheumatology 2005 Apr;32(4):713-20
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/ TNFSF10-induced Cyto-toxicity and Neutral-ization by Human Osteoprotegerin/ TNFRSF11B Antibody. In the presence of the metabolic inhibitor actinomycin D (0.5 µg/mL), Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (Catalog # 805-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/ TNFSF10 (50 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Osteoprotegerin/TNFRSF11B Monoclonal Antibody (Catalog # MAB805). The ND50 is typically 0.15-0.3 µg/mL.